Two Sigma Investments, LP Gilead Sciences, Inc. Transaction History

Two Sigma Investments, LP

$42.3 Billion
Q3 2024

A detailed history of Two Sigma Investments, LP transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 698,674 shares of GILD stock, worth $65.6 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

698,674

Previous 3,333,607 79.04%

Holding current value

$65.6 Million

Previous $229 Million 74.4%

% of portfolio

0.14%

Previous 0.56%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$66.59 - $83.99 $175 Million - $221 Million	-2,634,933 Reduced 79.04%	698,674 $58.6 Million
Q2 2024 Aug 14, 2024	BUY	$63.15 - $72.88 $8.65 Million - $9.98 Million	136,934 Added 4.28%	3,333,607 $229 Million
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $227 Million - $277 Million	3,177,673 Added 16724.59%	3,196,673 $234 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $179 Million - $203 Million	-2,438,656 Reduced 99.23%	19,000 $1.54 Million
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $118 Million - $129 Million	1,602,283 Added 187.32%	2,457,656 $184 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $115 Million - $131 Million	-1,513,653 Reduced 63.89%	855,373 $65.9 Million
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $45.4 Million - $51.7 Million	-586,766 Reduced 19.85%	2,369,026 $197 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $37.7 Million - $54.1 Million	-605,147 Reduced 16.99%	2,955,792 $254 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $21.1 Million - $24.1 Million	355,044 Added 11.07%	3,560,939 $220 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $38.4 Million - $43.2 Million	664,765 Added 26.16%	3,205,895 $198 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $62.8 Million - $78.8 Million	1,085,059 Added 74.52%	2,541,130 $151 Million
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $108 Million - $123 Million	-1,669,899 Reduced 53.42%	1,456,071 $106 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $162 Million - $175 Million	2,392,373 Added 326.12%	3,125,970 $218 Million
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $36.7 Million - $40.1 Million	577,719 Added 370.62%	733,597 $50.5 Million
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $6.8 Million - $7.75 Million	120,105 Added 335.74%	155,878 $9.08 Million
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $12.4 Million - $15.8 Million	-197,232 Reduced 84.65%	35,773 $2.67 Million
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $41.9 Million - $46.1 Million	-680,479 Reduced 74.49%	233,005 $15.1 Million
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $97.5 Million - $108 Million	-1,560,212 Reduced 63.07%	913,484 $57.9 Million
Q2 2019 Aug 14, 2019	SELL	$61.87 - $69.38 $21.7 Million - $24.3 Million	-350,685 Reduced 12.42%	2,473,696 $167 Million
Q1 2019 May 15, 2019	BUY	$62.53 - $70.05 $59.3 Million - $66.4 Million	947,758 Added 50.5%	2,824,381 $184 Million
Q4 2018 Feb 14, 2019	BUY	$60.54 - $79.0 $75.7 Million - $98.8 Million	1,250,898 Added 199.91%	1,876,623 $117 Million
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $24.5 Million - $27.1 Million	343,520 Added 121.73%	625,725 $48.3 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $14.8 Million - $17.3 Million	228,720 Added 427.63%	282,205 $20 Million
Q1 2018 May 15, 2018	SELL	$72.84 - $88.8 $25.9 Million - $31.6 Million	-355,720 Reduced 86.93%	53,485 $4.03 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $22.3 Million - $26.1 Million	-313,068 Reduced 43.34%	409,205 $29.3 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $52.1 Million - $61.7 Million	722,273	722,273 $58.5 Million

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Account

Two Sigma Investments, LP Gilead Sciences, Inc. Transaction History